SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Details Narrative) - USD ($)										3 Months Ended	12 Months Ended
	Dec. 31, 2021	Sep. 16, 2021	Feb. 11, 2021	Jan. 31, 2021	Jan. 14, 2021	Dec. 30, 2020	Dec. 08, 2020	Sep. 25, 2020	Jul. 21, 2020	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Class of Stock [Line Items]
Common Stock, Voting Rights											The holders of the Company’s common stock (“Common Stock”) are entitled to one vote per share
Common stock, shares authorized	100,000,000										100,000,000	100,000,000
Preferred Stock, shares authorized	20,000,000										20,000,000	20,000,000
[custom:StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable]												$ 756,523
Proceeds from Related Party Debt									$ 22,000
Number of shares issued											221,653
Class of warrant exercise price per share	$ 4.66										$ 4.66
Warrants and Rights Outstanding, Term												5 years
Proceeds from Issuance of Warrants											$ 3,285,171
Stock Issued During Period, Value, New Issues												$ 756,523
Convertible Preferred Stock, Shares Issued upon Conversion												250,000
Stock option Exercised											143,976
Cashless issuance of common stock	134,246										134,246
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross											124,100	378,800
[custom:InducementExpense]											$ 1,125,291	$ 802,109
Exchange of common stock warrants											109,372
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	221,653										221,653
Class of warrant exercised	109,372										109,372
Purchase of warrant outstanding											973,190
Purchase of common stock											658,771
Inducement expenses related to fair value of new award											$ 826,577
Share-based Payment Arrangement, Option [Member]
Class of Stock [Line Items]
Stock based compensation expenses											60,856	1,977,155
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 497,384										$ 497,384
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross										560,404
Equity Option [Member]
Class of Stock [Line Items]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition											2 years 7 months 6 days
Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Stock based compensation expenses											$ 12,304,514	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross										325,410
Common stock , shares issued restricted stock awards											2,785,820
Number of shares vested											0
Restricted Stock Units (RSUs) [Member] | Long Term Incentive Plan [Member]
Class of Stock [Line Items]
Number of shares vested											3,100,613
Restricted Stock [Member]
Class of Stock [Line Items]
Stock based compensation expenses											$ 231,631	$ 0
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	24,263										$ 24,263
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition											7 months 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross										42,125
[custom:InducementExpense]										$ 298,714
Common stock , shares issued restricted stock awards											74,224
Restricted Stock [Member] | Long Term Incentive Plan [Member]
Class of Stock [Line Items]
Number of shares vested											2,785,820
Restricted Stock units outstanding											5,886,433
Exchange of common stock warrants											297,635
Magic med industries [Member]
Class of Stock [Line Items]
Number of shares issued		9,951,217
[custom:SaleOfStockNumberOfValuesIssuedInTransaction]		$ 39,042,282
General and Administrative Expense [Member] | Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Stock based compensation expenses											$ 11,463,870
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 7,774,089										$ 7,774,089
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition											3 years 4 months 24 days
Research and Development Expense [Member] | Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Stock based compensation expenses											$ 840,644
Tikkun pharma Inc [Member]
Class of Stock [Line Items]
Number of shares issued												571,987
[custom:SaleOfStockNumberOfValuesIssuedInTransaction]												$ 1,900,546
Consideration of purchase price												1,944,689
Cash considerations												$ 44,143
Ameri [Member]
Class of Stock [Line Items]
Number of shares issued	221,653
Offering [Member] | Expense [Member]
Class of Stock [Line Items]
Proceeds from Issuance Initial Public Offering			$ 527,000		$ 663,000
Consultant [Member]
Class of Stock [Line Items]
Number of shares issued	14,121
Stock Issued During Period, Value, New Issues	$ 33,467
Common Stock [Member]
Class of Stock [Line Items]
Debt Conversion, Converted Instrument, Shares Issued						2,473,848			239,326
Number of shares issued												433,047
Stock Issued During Period, Value, New Issues												$ 4,330
Stock Issued During Period, Shares, Conversion of Convertible Securities											3,275,407	402,988
Common Stock [Member] | Restricted Stock [Member]
Class of Stock [Line Items]
Common stock , shares issued restricted stock awards											42,125
Common Stock [Member] | September Private Placement [Member]
Class of Stock [Line Items]
Number of shares issued								36,871
Proceeds from Issuance of Private Placement								$ 250,000
Sale of Stock, Consideration Received on Transaction								$ 227,500
Common Stock [Member] | Offering [Member]
Class of Stock [Line Items]
Number of shares issued			3,007,026		2,221,334
Class of warrant exercise price per share					$ 4.50
Proceeds from Issuance of Warrants			$ 12,800,000		$ 10,000,000
Common Stock [Member] | February 2019 Note [Member]
Class of Stock [Line Items]
Debt Instrument, Face Amount									$ 66,000
Common Stock [Member] | March 2019 Note [Member]
Class of Stock [Line Items]
Debt Instrument, Face Amount									$ 150,000
Common Stock [Member] | Vendors [Member].
Class of Stock [Line Items]
Common stock issued for accounts payable, shares.												433,047
[custom:StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable]												$ 756,523
Common Stock [Member] | Holder [Member]
Class of Stock [Line Items]
Number of shares issued											973,190
Warrant [Member]
Class of Stock [Line Items]
Number of shares issued											2,643,047
Proceeds from Issuance of Warrants											$ 3,285,171
Stock Issued During Period, Value, New Issues											$ 134,246
Stock Issued During Period, Shares, Conversion of Convertible Securities				1,015,315
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross												3,701,730
Exchange of common stock warrants											658,771
Warrant [Member] | Offering [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			1,503,513		1,666,019
Shares Issued, Price Per Share			$ 4.90		$ 4.95
Warrants and Rights Outstanding, Term			5 years		5 years
Proceeds from Issuance Initial Public Offering			$ 11,624,401		$ 8,800,087
[custom:AmountAllocatedToShareCapital]			7,016,401		4,617,087
[custom:AmountAllocatedToWarrantLiability]			$ 5,135,000		$ 4,846,000
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, shares authorized	3,600,000										3,600,000	3,600,000
Number of shares issued											3,275,407	3,275,407
Number of shares issued							221,225
Proceeds from issuance preferred stock							$ 300,000
Proceeds from issuance or sale of equity							$ 260,500
Convertible Preferred Stock, Shares Issued upon Conversion												250,000